跳至主要内容
临床试验/KCT0006371
KCT0006371招募中未知

Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla, prospective, multi-center, single-arm study

Samsung Medical Center0 个研究点目标入组 178 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
入组人数
178

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20?(Year) 至 69?(Year)(—)
性别
Female

入选标准

  • 1) undergone neoadjuvant chemotherapy
  • 2) HER-2 or triple negative breast cancer
  • 3) clinical stage T1-3, N0-1, M0 (AJCC 8th)
  • 4) not Inflammatory breast cancer
  • 5) neoadjuvant chemotherapy should be done before surgery(sandwich method is not allowed)
  • - least four times anthacycline or taxane-based regimens
  • - no axilla lesion progression during chemotherapy
  • - no period of adverse response during chemotherapy
  • 6) undergone anti HER-2 therapy in HER-2 positive patient
  • 7) no preoperative anti hormonal therapy
  • 8) no preoperative radiation therapy?
  • 9) did not axillary lymph node biopsy before neoadjuvant chemotherapy
  • 10) physical examination expected complete remission. And radiological expected Tumor size = 2cm or non-mass enhancement = 4cm
  • 11) no previous axilla surgery
  • 12) no previous ipsilateral breast surgery for invasive cancer
  • 13) no Pregnancy-associated breast cancer
  • 14) ECOG performance status 0-1
  • 15) Serum or urine b-HCG negative
  • 16) agree to the consent form
  • 17) 20=Age<70

排除标准

  • 1) During pregnancy
  • 2) major depression or taking psychiatric medication
  • 3) significant psychiatric disorder or history of taking antipsychotic drugs
  • 4) any other lymph node metastasis than axillary lesion
  • 5) undergoing total mastectomy
  • 6) do not agree to the consent form

研究者

相似试验